Neeraj Agarwal: Results from Ph3 TALAPRO-2 trial in 399 pts w/ HRR-deficient mCRPC prostate cancer

Neeraj Agarwal shared the following on Twitter:

“Just in Nature Medicine: Results from Ph3 TALAPRO-2 trial in 399 pts w/ HRR-deficient mCRPC prostate cancer enza + tala vs. enza, rPFS HR 0.44, OS trending strongly HR 0.69, efficacy in multiple HRR gene subsets”

For details click here.
Source: Neeraj Agarwal/Twitter

Neeraj Agarwal is a Professor of medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI. Dr. Agarwal is an Advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, leads early therapeutics in the SWOG genitourinary cancers committee, and is the Chief Editor of ASCO Daily News.